New combo could ease anemia for kidney patients on dialysis

NCT ID NCT06115421

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a low dose of the drug Roxadustat, combined with iron, can safely and effectively treat anemia in people with kidney disease who are on dialysis. The trial involved 72 adults and compared the combination to standard treatment with erythropoietin-stimulating agents. Researchers measured changes in hemoglobin levels, iron levels, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Roxadustat (a drug that helps the body produce more red blood cells) plus iron

What this could lead to

If successful, this could offer a safer, lower-dose option to manage anemia in dialysis patients, potentially reducing side effects and improving quality of life.

What could go wrong

This is a small, completed Phase 4 trial with only 72 participants. Results may not apply to all patients, and the drug may still cause side effects or not work as well as standard treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA IN DIALYSIS-DEPENDENT CKD PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Alexandria University

    Alexandria, Egypt